SNIFF - 3-Week Aptar CPS Device
Key facts
- Who runs it
- Wake Forest University Health Sciences
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- May 2025
- Expected to end
- May 2031
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Insulin (Humulin® R U-100)
- Placebo
- Aptar Pharma CPS Intranasal Delivery Device
- Record updated
- 28 July 2025
- Why it stopped
- protocol being rewritten and submitted as new study
Who can take part
- Age
- 55 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Age 55 to 85 (inclusive)
- Fluent in English
- Cognitively normal or diagnosis of amnestic mild cognitive impairment (aMCI) or mild Alzheimer's disease (AD)
- Amyloid positive by positron emission tomography (PET) or cerebrospinal fluid (CSF) criteria
- Stable medical condition for 3 months prior to screening visit
- Stable medications for 4 weeks prior to the screening and study visits (exceptions may be made on a case by case basis by the study physician)
- Clinical laboratory values must be within normal limits or, if abnormal, must be judged to be clinically insignificant by the study physician
Who cannot take part
- Current or past regular use of insulin or any other anti-diabetic medication within 2 months of screening visit
- Use of an investigational agent within two months of screening visit
- Regular use of alcohol, narcotics, anticonvulsants, anti-parkinsonian medications, or any other exclusionary medications (exceptions may be made on a case by case basis by the study physician)
- A diagnosis of dementia other than Alzheimer's disease (AD)
- History of a clinically significant stroke
- Current evidence or history in past two years of epilepsy, head injury with loss of consciousness, any major psychiatric disorder including psychosis, major depression, bipolar disorder
- Diabetes (type I or type II) insulin-dependent and non-insulin-dependent diabetes mellitus
- History of seizure within past five years
- Pregnancy or possible pregnancy
- Use of anticoagulants
- Residence in a skilled nursing facility at screening
About the trial
What the trial wants to find out
The SNIFF 3-Week Aptar Device study will involve using a device to administer insulin or placebo through each participant's nose or intra-nasally. Insulin is a hormone that is produced in the body. It works by lowering levels of glucose (sugar) in the blood. This study is measuring how much insulin the device delivers. In addition, this study will look at the effects of insulin or placebo administered intra-nasally using an intranasal delivery device on memory, blood, and cerebrospinal fluid (CSF).
The 2 groups in the trial
- Humulin® R U-100Treatment being tested
Twenty randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive intranasal administrations of Humulin® R U-100 (40 IU) four times daily for 3 weeks.
Treatment: Insulin (Humulin® R U-100) and Aptar Pharma CPS Intranasal Delivery Device
- PlaceboPlacebo, for comparison
Twenty randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive intranasal administrations of placebo (insulin diluent) four times daily for 3 weeks.
Treatment: Placebo and Aptar Pharma CPS Intranasal Delivery Device
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Study of Nasal Insulin to Fight Forgetfulness (SNIFF) - 3-Week Aptar CPS Device
- Record updated
- 28 July 2025